Cytokine storm is an immune reaction to an acute or chronic injury and may be caused by a disease itself or by treatment directed at an underlying disease. The result is an overwhelming release of cytokines which can cause a sepsis-like response and may lead to multi-system organ failure and even death. Because it occurs in various settings, oncology nurses need to be aware of this process when assessing the pediatric oncology patient. Early recognition and treatment initiation is imperative and may lead to better outcomes for the patient.
Breslin, S. ( 2007). Cytokine-release syndrome: Overview and nursing implications . Clinical Journal of Oncology Nursing, 11, 37-42.
2.
Bugelski, P., Achuthanandam, R., Capocasale, R., Treacy, G., & Bouman-Thio, E. (2007). Monoclonal antibody-induced cytokine-release syndrome. Expert Reviews in Clinical Immunology , 5, 499-521.
3.
Centers for Disease Control and Prevention. ( 2006). Deaths and mortality. Retrieved from http://www.cdc.gov/nchs/FASTATS/deaths.htm
4.
Cheng, J., & Sakamoto, K. ( 2005). Topics in pediatric leukemia: Acute myeloid leukemia . Medscape General Medicine. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1681379/
5.
Doyle, S. ( 2005). Bone marrow. In D. Tomlinson & N. Kline (Eds.), Pediatric oncology nursing: Advanced clinical handbook (pp. 274-288). New York, NY: Springer-Verlag.
6.
Dragotta, M., Woodruff, B., & Bills, D. ( 2006). Septic shock. In M. Slota (Ed.), Core curriculum for pediatric critical care nursing (2nd ed., pp. 721-746). St. Louis, MO: Saunders Elsevier.
7.
Fujii, H., Cuvelier, G., She, K., Aslanian, S., Shimizu, H., Kariminia, A., . . . Schultz, K.R. ( 2008). Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: A report from the Children’s Oncology Group . Blood, 111, 3276-3285.
8.
Giulino, L., Bussel, J., & Neufeld, E. ( 2007). Treatment with rituximab in benign and malignant hematologic disorders in children. Journal of Pediatrics, 150, 338el-344e1.
9.
Hall, A. ( 2005). Cardiovascular system. In D. Tomlinson & N. Kline (Eds.), Pediatric oncology nursing: Advanced clinical handbook (pp. 327-336). New York, NY: Springer-Verlag.
10.
Jeha, S., Gaynon, P., Razzouk, B., Franklin, J., Kadota, R., Shen, V., . . . Steinherz, P. ( 2006). Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Journal of Clinical Oncology, 24, 1917-1922.
11.
Ladisch, S. ( 2007). Histiocytosis syndromes of childhood. In R. Kliegman, R. Behrman, H. Jenson, & B. Stanton (Eds.), Nelson textbook of pediatrics (18th ed., pp. 2159-2162). Philadelphia, PA: Saunders Elsevier.
12.
Marieb, E. (Ed.). (2001). The immune system: Innate and adaptive body defenses. In Human Anatomy & Physiology (5th ed., pp. 793-827). San Francisco, CA: Benjamin Cummins.
13.
Mischler, M., Fleming, G.M., Shanley, T.P., Madden, L., Levine, J., Castle, V., . . . Cornell, T.T. ( 2007). Epstein-Barr virus-induced hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease: A mimicker of sepsis in the pediatric intensive care unit. Pediatrics, 119, e1212-e1218.
14.
Norville, R. ( 2005). Hematopoietic stem cell transplantation. In D. Tomlinson & N. Kline (Eds.), Pediatric oncology nursing: Advanced clinical handbook (pp. 201-217). New York, NY: Springer-Verlag.
15.
Panelli, M., White, R., Foster, M., Martin, B., Wang, E., Smith, K., & Marincola, F.M. (2004). Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. Journal of Translational Medicine, 2, 17.
16.
Ponce, R. ( 2008). Adverse consequences of immunostimulation. Journal of Immunotoxicology, 5, 33-41.
17.
Prescott, L., Harley, J. , & Klein, D. (Eds.). (2002). Microbiology (5th ed.). New York, NY: McGraw-Hill.
18.
Schwinger, W., Klass, V., Benesch, M., Lackner, H., Dornbusch, H., Sovinz, P., . . . Urban, C. ( 2005). Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Annals of Oncology, 16, 1199-1206.
19.
Soares, M., Feres, G., Salluh, J. ( 2009). Systemic inflammatory response syndrome and multiple organ dysfunction in patients with acute tumor lysis syndrome. Clinics, 64, 479-481.
20.
St. Clair, E. ( 2008). The calm after the cytokine storm: Lessons from the TN1412 trial. Journal of Clinical Investigation, 118, 1344-1347.
21.
Sun, Y., Tawara, I., Toubai, T., & Reddy, P. ( 2007). Pathophysiology of acute graft-versus-host disease: Recent advances. Translational Research, 150, 197-214.
22.
Wadhwa, M., & Thorpe, R. ( 2008). Haematopoietic growth factors and their therapeutic use . Thrombosis and Haemostasis, 99, 863-873.
23.
Wang, H., & Ma, S. ( 2008). The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. American Journal of Emergency Medicine, 26, 711-715.
